CY1114586T1 - Συνθεση φορεα για τη μεταφορα νουκλεϊνικων οξεων - Google Patents
Συνθεση φορεα για τη μεταφορα νουκλεϊνικων οξεωνInfo
- Publication number
- CY1114586T1 CY1114586T1 CY20131100464T CY131100464T CY1114586T1 CY 1114586 T1 CY1114586 T1 CY 1114586T1 CY 20131100464 T CY20131100464 T CY 20131100464T CY 131100464 T CY131100464 T CY 131100464T CY 1114586 T1 CY1114586 T1 CY 1114586T1
- Authority
- CY
- Cyprus
- Prior art keywords
- composition
- nucleic acid
- transfer
- acid transport
- carbon composition
- Prior art date
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 7
- 150000007523 nucleic acids Chemical class 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 7
- -1 cationic lipid Chemical class 0.000 abstract 2
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 125000002345 steroid group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005303497 | 2005-10-18 | ||
| EP06811872.8A EP1946761B8 (en) | 2005-10-18 | 2006-10-17 | Carrier composition for nucleic acid transport |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114586T1 true CY1114586T1 (el) | 2016-10-05 |
Family
ID=37962449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100464T CY1114586T1 (el) | 2005-10-18 | 2013-06-11 | Συνθεση φορεα για τη μεταφορα νουκλεϊνικων οξεων |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8030075B2 (https=) |
| EP (1) | EP1946761B8 (https=) |
| JP (1) | JP5046952B2 (https=) |
| KR (1) | KR101324065B1 (https=) |
| CN (2) | CN101291678B (https=) |
| AR (1) | AR057553A1 (https=) |
| AU (1) | AU2006305318B2 (https=) |
| BR (1) | BRPI0617449A2 (https=) |
| CA (1) | CA2624840A1 (https=) |
| CY (1) | CY1114586T1 (https=) |
| DK (1) | DK1946761T3 (https=) |
| ES (1) | ES2412029T3 (https=) |
| MY (1) | MY149502A (https=) |
| PL (1) | PL1946761T3 (https=) |
| PT (1) | PT1946761E (https=) |
| RU (1) | RU2421227C2 (https=) |
| SI (1) | SI1946761T1 (https=) |
| TW (1) | TW200800235A (https=) |
| WO (1) | WO2007046356A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200800235A (en) * | 2005-10-18 | 2008-01-01 | Otsuka Pharma Co Ltd | Carrier composition for nucleic acid transport |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| WO2011114678A1 (ja) * | 2010-03-15 | 2011-09-22 | 国立大学法人山口大学 | 哺乳動物細胞への遺伝子導入効率の向上剤 |
| US9750819B2 (en) * | 2012-05-23 | 2017-09-05 | Ohio State Innovation Foundation | Lipid nanoparticle compositions and methods of making and methods of using the same |
| US9833416B2 (en) * | 2014-04-04 | 2017-12-05 | Ohio State Innovation Foundation | Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same |
| EP3329011B1 (en) * | 2015-07-30 | 2019-12-18 | Arcis Biotechnology Holdings Limited | Method and composition |
| CN117481114A (zh) * | 2023-10-27 | 2024-02-02 | 硅羿科技（上海）有限公司 | 纳米核酸农药、其制备方法和应用、以及核酸递送系统 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US6020317A (en) * | 1993-02-19 | 2000-02-01 | Nippon Shinyaku Co. Ltd. | Glycerol derivative, device and pharmaceutical composition |
| US20030092180A1 (en) | 2001-08-27 | 2003-05-15 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
| US5965542A (en) * | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
| GB9726398D0 (en) * | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
| DK1129064T3 (da) * | 1998-11-12 | 2008-04-28 | Invitrogen Corp | Transfektionsreagenser |
| HUP9902217A3 (en) * | 1999-06-29 | 2002-07-29 | Szegoe Peter | Polycation based bioconjugates and process for producing thereof |
| AU2002214854A1 (en) * | 2000-10-25 | 2002-05-06 | Inex Pharmaceuticals Corporation | Lipid formulations for target delivery |
| WO2002060412A2 (en) * | 2001-02-01 | 2002-08-08 | Board Of Regents | Stabilised polymeric aerosols for pulmonary gene delivery |
| US20030096414A1 (en) * | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
| US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| EP1575976A4 (en) * | 2001-11-02 | 2006-08-23 | Insert Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE |
| ES2279127T3 (es) * | 2002-07-05 | 2007-08-16 | Lipoxen Technologies Limited | Procedimiento para aumentar una respuesta inmunitaria de vacunacion de acido nucleico. |
| ES2559828T3 (es) * | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| AU2005310131A1 (en) * | 2004-11-17 | 2006-06-08 | University Of Maryland, Baltimore | Highly branched HK peptides as effective carriers of siRNA |
| US20070087045A1 (en) * | 2005-10-14 | 2007-04-19 | Industrial Technology Research Institute | Lipid carrier and method of preparing the same |
| TW200800235A (en) * | 2005-10-18 | 2008-01-01 | Otsuka Pharma Co Ltd | Carrier composition for nucleic acid transport |
-
2006
- 2006-10-16 TW TW095138027A patent/TW200800235A/zh not_active IP Right Cessation
- 2006-10-17 MY MYPI20081086A patent/MY149502A/en unknown
- 2006-10-17 BR BRPI0617449-3A patent/BRPI0617449A2/pt not_active IP Right Cessation
- 2006-10-17 ES ES06811872T patent/ES2412029T3/es active Active
- 2006-10-17 CN CN2006800389545A patent/CN101291678B/zh not_active Expired - Fee Related
- 2006-10-17 US US12/083,727 patent/US8030075B2/en not_active Expired - Fee Related
- 2006-10-17 AU AU2006305318A patent/AU2006305318B2/en not_active Ceased
- 2006-10-17 KR KR1020087011745A patent/KR101324065B1/ko not_active Expired - Fee Related
- 2006-10-17 SI SI200631574T patent/SI1946761T1/sl unknown
- 2006-10-17 RU RU2008119498/15A patent/RU2421227C2/ru not_active IP Right Cessation
- 2006-10-17 WO PCT/JP2006/320617 patent/WO2007046356A1/ja not_active Ceased
- 2006-10-17 JP JP2007540975A patent/JP5046952B2/ja not_active Expired - Fee Related
- 2006-10-17 PL PL06811872T patent/PL1946761T3/pl unknown
- 2006-10-17 CN CN201110461144.3A patent/CN102512689B/zh not_active Expired - Fee Related
- 2006-10-17 DK DK06811872.8T patent/DK1946761T3/da active
- 2006-10-17 EP EP06811872.8A patent/EP1946761B8/en not_active Not-in-force
- 2006-10-17 PT PT68118728T patent/PT1946761E/pt unknown
- 2006-10-17 AR ARP060104512A patent/AR057553A1/es unknown
- 2006-10-17 CA CA002624840A patent/CA2624840A1/en not_active Abandoned
-
2013
- 2013-06-11 CY CY20131100464T patent/CY1114586T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007046356A1 (ja) | 2007-04-26 |
| EP1946761A1 (en) | 2008-07-23 |
| EP1946761A4 (en) | 2012-01-25 |
| CN101291678A (zh) | 2008-10-22 |
| DK1946761T3 (da) | 2013-04-15 |
| US8030075B2 (en) | 2011-10-04 |
| RU2421227C2 (ru) | 2011-06-20 |
| EP1946761B1 (en) | 2013-04-03 |
| US20090258923A1 (en) | 2009-10-15 |
| MY149502A (en) | 2013-09-13 |
| KR20080059648A (ko) | 2008-06-30 |
| CA2624840A1 (en) | 2007-04-26 |
| JP5046952B2 (ja) | 2012-10-10 |
| AU2006305318A1 (en) | 2007-04-26 |
| CN102512689A (zh) | 2012-06-27 |
| PL1946761T3 (pl) | 2013-08-30 |
| SI1946761T1 (sl) | 2013-06-28 |
| EP1946761B8 (en) | 2013-05-22 |
| KR101324065B1 (ko) | 2013-10-31 |
| ES2412029T3 (es) | 2013-07-09 |
| PT1946761E (pt) | 2013-05-27 |
| AR057553A1 (es) | 2007-12-05 |
| TWI376225B (https=) | 2012-11-11 |
| RU2008119498A (ru) | 2009-11-27 |
| JPWO2007046356A1 (ja) | 2009-04-23 |
| AU2006305318B2 (en) | 2011-08-25 |
| HK1119956A1 (en) | 2009-03-20 |
| CN101291678B (zh) | 2012-03-28 |
| CN102512689B (zh) | 2014-08-20 |
| TW200800235A (en) | 2008-01-01 |
| BRPI0617449A2 (pt) | 2011-07-26 |
| HK1171689A1 (en) | 2013-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114586T1 (el) | Συνθεση φορεα για τη μεταφορα νουκλεϊνικων οξεων | |
| Bertran-Gonzalez et al. | Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol | |
| Sadoon et al. | Silver ions caused faster diffusive dynamics of histone-like nucleoid-structuring proteins in live bacteria | |
| Iftikar et al. | Could thermal sensitivity of mitochondria determine species distribution in a changing climate? | |
| Gonzalez et al. | Abnormal mitochondrial fusion–fission balance contributes to the progression of experimental sepsis | |
| Summerton | Endo‐Porter: A novel reagent for safe, effective delivery of substances into cells | |
| FI944773A0 (fi) | Asymmetriset synteesit | |
| Podrabsky et al. | Cell cycle regulation during development and dormancy in embryos of the annual killifish Austrofundulus limnaeus | |
| Palencia-Gándara et al. | Conjugation inhibitors effectively prevent plasmid transmission in natural environments | |
| Hammill et al. | Synthesis, derivatization and photochemical control of ortho‐functionalized tetrachlorinated azobenzene‐modified siRNAs | |
| Toleikis et al. | Fatty acid oxidation and mitochondrial morphology changes as key modulators of the affinity for ADP in rat heart mitochondria | |
| Fatemi Tabatabaie et al. | Silver nanoparticle exposure in pregnant rats increases gene expression of tyrosine hydroxylase and monoamine oxidase in offspring brain | |
| CY1116189T1 (el) | Σταθερη υγρη φαρμακευτικη συνθεση με βαση την τραζοδονη | |
| Nakamura et al. | In vitro and in vivo gene delivery with tailor‐designed aminofullerenes | |
| Rasamizafy et al. | Mitotic acetylation of microtubules promotes centrosomal PLK1 recruitment and is required to maintain bipolar spindle homeostasis | |
| Makhadmeh et al. | Photodynamic application of protoporphyrin IX as a photosensitizer encapsulated by silica nanoparticles | |
| Pucci et al. | Evaluation of epigenetic and radiomodifying effects during radiotherapy treatments in zebrafish | |
| Yang et al. | Response of juvenile crucian carp (Carassius auratus) to long-term ammonia exposure: feeding, growth, and antioxidant defenses | |
| CY1112029T1 (el) | Συνθετο νουκλεϊνικο οξυ και συνθεση απελευθερωσης νουκλεϊνικου οξεος | |
| MY151450A (en) | Prompt nucleic acid delivery carrier composition | |
| Akera et al. | The spindle assembly checkpoint promotes chromosome bi-orientation: a novel Mad1 role in chromosome alignment | |
| Lewis Jr et al. | Sulfonium ion condensation: the burden borne by SAM synthetase | |
| Cahill et al. | Screening for negative effects of candidate ascidian antifoulant compounds on a target aquaculture species, Perna canaliculus Gmelin | |
| Victorio et al. | Peptide-conjugated phosphorodiamidate morpholino oligomers for in situ live-cell molecular imaging of dengue virus replication | |
| MY199389A (en) | Methods of preserving the biological activity or ribonucleic acids |